Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients

What is known and objective Sofosbuvir has been approved as the first nonstructural protein 5B polymerase inhibitor with pan‐genotypic activity against the hepatitis C (HCV) virus. Daclatasvir is a first‐in‐class hepatitis C virus nonstructural protein 5A replication complex inhibitor. We aimed to evaluate the usefulness of the reference single nucleotide polymorphism (rs12979860) interleukin 28B (CC genotype) for predicting sustained virological response to sofosbuvir plus daclatasvir in Egyptian patients infected with HCV‐4. Methods Samples were collected at week zero. One hundred and thirty‐one patients who reached the end of treatment (at week 12) were divided into three groups, according to their interleukin 28B genotype: Group A included 31 patients (CC genotype), group B included 79 patients (CT genotype) and group C had 21 patients (TT genotype). All patients received treatment for 3 months in the form of sofosbuvir plus daclatasvir with ribavirin (in case of cirrhotic patients) or without ribavirin (in case of non‐cirrhotic patients). Results and discussion Sustained virological response rate was significantly higher in patients with IL28B (CC genotype) vs. (non‐CC genotype) (100 vs.88%) (p